Trial Profile

Asthma Exacerbation Profile in Patients on Open Label Treatment With Benralizumab for Severe Eosinophilic Asthma - an Exploratory Cohort Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Acute asthma
Focus Therapeutic Use
Acronyms BenRex

Most Recent Events

24 Apr 2024 Status changed from active, no longer recruiting to completed.
07 Mar 2023 Status changed from recruiting to active, no longer recruiting.
06 Jul 2021 The study protocol amended to change frequency of Benralizumab to 30mg by subcutaneous injection, 18 months treatment for the first 75 participants enrolled, 12 months treatment for participants 76-150 from every 4 weeks

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com